Table 1.
Clinical studies with catumaxomab
| Completed | |||
| Indication | Reference | Phase | No. of catumaxomab treated patients |
| Malignant ascites due to ovarian cancer | Ref. 11 (Burges et al. 2007) | 1/2 | 23 |
| Malignant ascites due to epithelial tumours (PK/PD study) | Ref. 12 (Ruf et al. 2008) | 2 | 13 |
| Malignant ascites due to epithelial tumours (pivotal study) | NCT00836654; Ref. 13 (Parsons et al. 2008) | 2/3 | 157 |
| Platinum refractory epithelial ovarian cancer (i.p. application) | AGO-Ovar 2.10, nCT00189345; Ref. 24 (Belau et al. 2007) | 2a | 45 |
| Peritoneal carcinomatosis due to epithelial gastrointestinal malignancies (i.p. application) | Ref. 14 (Ströhlein et al. 2009) | 1 | 24 |
| Intra-abdominal epithelial tumours (i.o. and i.p. application) | Ref. 27 (Ströhlein et al. 2008) | 1 | 12 |
| Malignant pleural effusion (i.pl. application) | Ref. 15 (Sebastian et al. 2009) | 1/2 | 24 |
| Non-small cell lung cancer (i.v. application) | Ref. 16 (Sebastian et al. 2007) | 1 | 21 |
| Ongoing | |||
| Gastric cancer (i.o. and i.p. application) | NCT00352833; Ref. 30 (Heiss et al. 2008) | 2 | 28 |
| Gastric cancer (i.o. and i.p. application after neoadjuvant CTx) | NCT00464893 | 2 | 54 |
| Ovarian cancer (consolidation, i.p. application) | NCT00377429 | 2 | 47 |
| Ovarian cancer (i.o. and i.p. application) | NCT00563836 | 2 | 41 |
| Malignant ascites due to ovarian cancer (i.p. application) | NCT00326885 | 2 | 35 (planned) |
| CASIMAS, malignant ascites due to epithelial carcinomas (i.p. application) | NCT00822809 | 3 | 156 (planned) |
| SECIMAS, malignant ascites due to epithelial carcinomas (i.p. application) | 2 | 30 (planned) | |
| Optimal interval between CTx and catumaxomab | in vitro | 30 (planned) | |
| Under discussion | |||
| Peritoneal carcinomatosis due to metastatic gastric adenocarcinoma | 3 | ||